middle.news
INOVIQ’s EXO-OC Test Hits 100% Early Detection Sensitivity in Ovarian Cancer
9:12am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
INOVIQ’s EXO-OC Test Hits 100% Early Detection Sensitivity in Ovarian Cancer
9:12am on Thursday 31st of July, 2025 AEST
Key Points
EXO-OC test achieves 100% sensitivity for early-stage ovarian cancer with no false positives
Provisional patent filed to protect EXO-OC intellectual property
CAR-exosome therapy kills 88% of triple negative breast and lung cancer cells in vitro
Cash position of $6.5 million with ongoing R&D investment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE